Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 versus placebo plus best supportive care in refractory metastatic colorectal cancer
2012-000109-66Phase 3Completed
- Sponsor
- Taiho Oncology
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) comparing TAS-102 plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Jun 2012; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-000109-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000109-66.